Adageis, a healthcare technology company, is taking a bold stance in reshaping the healthcare landscape by prioritizing providers in the transition to value-based care. Unlike traditional models that often burden clinicians with administrative complexities, the Adageis provider-centric focus offers solutions designed to streamline workflows and align incentives with quality care outcomes.
Central to this approach is the company’s ProActive Care Platform, a patented AI-powered system that provides actionable insights to healthcare providers. The platform equips Accountable Care Organizations (“ACOs”), Clinically Integrated Networks (“CINs”), and Independent Physician Associations (“IPAs”) with the tools to deliver high-quality care while meeting the financial goals of value-based models.
By giving providers access to advanced analytics and risk management tools, the company ensures that clinicians can take proactive steps to improve patient outcomes. Providers using Adageis’s solutions gain the ability to monitor patient health in real time, address potential complications early, and maintain a clear focus on quality care metrics.
A significant advantage of the Adageis platform is its ability to integrate with leading EHR systems, including AthenaHealth, eClinicalWorks, Allscripts, Cerner, and Epic. This ensures that providers can adopt the technology without overhauling existing systems or undergoing extensive training.
At the heart of the platform lies the Patented Risk Engine (“PRE”), an AI-driven tool that analyzes patient data to identify high-risk individuals and care gaps. This enables clinicians to prioritize interventions, improve outcomes and manage costs effectively.
The platform’s proactive efficiency allows users to continuously monitor patient health, allowing providers to take timely action beyond the confines of office visits. This not only improves efficiency but also reduces healthcare expenses by addressing issues early.
A foundational factor that sets Adageis apart is its commitment to ease of use and impactful results. The company’s dashboard delivers insights in a user-friendly format, making it easier for providers to interpret and act on complex data. The flexibility of the platform is another differentiator. Its Value-Based Care Engine is a single solution designed to drive revenue through value-based care metrics while maintaining high standards of patient care.
As value-based care becomes the standard in the U.S., providers face mounting pressures to deliver better outcomes while controlling costs. Adageis is poised to address these challenges by offering a scalable solution that aligns with the goals of healthcare organizations and clinicians alike. By prioritizing a provider-centric approach, Adageis ensures that healthcare professionals are not only incentivized but also empowered to succeed in this developing landscape.
For more information, visit the company’s website at www.Adageis.com.
NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
The announcement outlines a strategic collaboration between HeartBeam and Mount Sinai to develop and validate…
For a long time, scientists have been working tirelessly to come up with vaccines against cancer. Significant progress is…
A landmark Phase III trial published in The Lancet demonstrated a five-year overall survival rate…
Soligenix is entering a pivotal period marked by several anticipated clinical readouts and milestones expected…
Designations granted by leading global regulatory agencies play a critical role in advancing drug-development programs.…
Enormous resources are being channeled into studying different ways to support the immune system in its fight…